Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain
{{output}}
Background: Etrasimod (2 mg orally, once daily) is a novel advanced therapy (AT) for patients aged 16 years and older, with moderately-to-severely active ulcerative colitis (UC). This cost-effectiveness analysis compared etrasimo... ...
